BioSpace News Archive

SOTIO Biotech announced today that it will deliver an oral presentation featuring interim safety and efficacy data from its Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, in combination with pembrolizumab, as well as two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022.

PolarityTE, Inc. today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Company’s President & CEO, David P. Luci, has been invited to present at the 2022 Virtual Growth Conference.

Helix BioPharma Corp. today announces, with great sadness, the sudden passing of its Interim Chief Executive Officer and Chairman of the Board of Directors, Prof. Dr. S Slawomir Majewski.

MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies.

IMMUNOPRECISE ANTIBODIES LTD. today announced financial results for third quarter fiscal year 2022, which ended January 31, 2022.

LIXTE Biotechnology Holdings, Inc. will present at the MedInvest Pharmaceutical and Biotechnology Investor Conference to be held March 28 - April 1, 2022.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the fourth quarter and full year 2021 and provided an update on recent corporate activities.

BioCircuit Technologies and Smithfield BioScience today announced the companies will produce Nerve Tape®, a medical device enabling suture-less nerve repair following traumatic injuries.

Thermo Fisher Scientific, the world leader in serving science, has introduced a new large-volume electroporation system that allows cell therapy developers to more easily move from clinical development to commercial manufacturing.